AI-TreatCancer AI-guided personalized T cell receptor transgenic T cell therapy against cancer
- Coordinator
- Deutsches Krebsforschungszentrum Heidelberg, Germany
- Runs
- 1 June 2026 to 30 November 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101293142
What the project is doing
In the project's own words, from its summary on CORDIS.
Personalised T cell therapy has shown remarkable success in cancer therapy, however the antigens that T cells recognize to kill tumor cells are dependent on the individual tumor, T cell receptor (TCR) profile and antigen presentation machinery. AI-TreatCancer will leverage predicTCR, a proprietary AI-guided classifier that identifies tumor-killing TCRs from patient samples, decreasing the time to identify therapeutic TCRs from 3-4 months to under 2 weeks.
In the ERC Advanced Grant (ERC-2023-ADG #101141901 — Characterizing and harnessing tumor-reactive T cells in the brain
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI